Oligodendroglioma pathophysiology

Revision as of 19:28, 17 January 2012 by Michael Maddaleni (talk | contribs) (Created page with "{{CMG}} {{Oligodendroglioma}} ==Overview== ==Molecular genetics== By far, the most common structural deformity found is co-deletion of chromosomal arms 1p and 19q. The high ...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Oligodendroglioma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Oligodendroglioma from other Diseases

Epidemiology & Demographics

Risk Factors

Screening

Natural History, Complications, and Prognosis

Diagnosis

Staging

History & Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Oligodendroglioma pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Oligodendroglioma pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Oligodendroglioma pathophysiology

CDC on Oligodendroglioma pathophysiology

Oligodendroglioma pathophysiology in the news

Blogs on Oligodendroglioma pathophysiology

Directions to Hospitals Treating Oligodendroglioma

Risk calculators and risk factors for Oligodendroglioma pathophysiology

Overview

Molecular genetics

By far, the most common structural deformity found is co-deletion of chromosomal arms 1p and 19q. The high frequency of co-deletion (60-80%) is a striking feature of this glial tumour, and is considered as a "genetic signature" of oligodendroglioma. 1p/19q deletion has been correlated with both chemosensitivity and improved prognosis in oligodendrogliomas.[1][2] A t(1;19)(q10;p10) translocation mediates the combined deletions of 1p and 19q. The gene products lost as a consequence of this codeletion may include mediators of resistance to genotoxic therapies. Alternatively, 1p/19q loss might be an early oncogenic lesion promoting the formation of glial neoplasms, which retain high sensitivity to genotoxic stress.

References

  1. Laigle-Donadey F, Benouaich-Amiel A, Hoang-Xuan K, Sanson M (2005). "[Molecular biology of oligodendroglial tumors]". Neuro-Chirurgie (in French). 51 (3-4 Pt 2): 260–8. PMID 16292170.
  2. Walker C, Haylock B, Husband D; et al. (2006). "Clinical use of genotype to predict chemosensitivity in oligodendroglial tumors". Neurology. 66 (11): 1661–7. doi:10.1212/01.wnl.0000218270.12495.9a. PMID 16769937.